Ipilimumab, a human IgG1 mAb directed against CTLA-4, mediates durable remissions in patients with advanced melanoma, although such responses are limited to a small subset (Hodi et al., 2010, Robert et al., 2011, Schadendorf et al., 2015). Here, CTLA4 is linked to melanoma.